Brokerages Set bluebird bio, Inc. (NASDAQ:BLUE) Target Price at $44.14

bluebird bio, Inc. (NASDAQ:BLUE) has been given an average rating of “Hold” by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $48.10.

Several equities research analysts have weighed in on BLUE shares. Royal Bank of Canada restated a “sector perform” rating and set a $80.00 target price on shares of bluebird bio in a research note on Friday, November 15th. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Wells Fargo & Company dropped their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, February 24th. Barclays increased their price target on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. Finally, Bank of America cut bluebird bio from a “buy” rating to a “neutral” rating and dropped their price target for the company from $60.00 to $10.00 in a research note on Friday, November 15th.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. bought a new position in bluebird bio during the 4th quarter worth $175,000. Verition Fund Management LLC acquired a new stake in shares of bluebird bio in the 3rd quarter valued at about $42,000. Captrust Financial Advisors grew its stake in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 77,293 shares during the period. Barclays PLC lifted its position in bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in bluebird bio by 2,270.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 355,562 shares in the last quarter. 87.43% of the stock is owned by institutional investors.

bluebird bio Stock Down 2.7 %

NASDAQ BLUE opened at $4.00 on Monday. The business has a fifty day moving average price of $6.92 and a two-hundred day moving average price of $8.58. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. bluebird bio has a fifty-two week low of $3.56 and a fifty-two week high of $33.20. The stock has a market capitalization of $38.89 million, a PE ratio of -0.11 and a beta of 0.76.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.